Clinical trials
Full profile accessFollow clinical development from study design and recruitment through results.
- Trial phase
- Status
- Readouts
Drug intelligence / Profile preview
AAV9-shCon is a research-grade viral vector used as a negative control in gene silencing experiments, particularly those involving RNA interference (RNAi). It consists of an adeno-associated virus serotype 9 (AAV9) capsid packaging a genetic payload that expresses a non-targeting, or 'scrambled,' short hairpin RNA (shRNA). AAV9 is a widely utilized vector in neuroscience due to its ability to cross the blood-brain barrier and efficiently transduce various CNS cell types, including neurons and astrocytes. In preclinical models of Alzheimer's disease and neurovascular dysfunction, AAV9-shCon serves as a critical baseline to control for the biological effects of viral transduction and shRNA expression, allowing researchers to isolate the specific effects of knocking down a target gene, such as Endoglin (ENG).
Beyond the preview
Explore the evidence, development activity, and competitive landscape with Gosset’s full data platform.
Follow clinical development from study design and recruitment through results.
Explore development by indication, patient population, and geography.
Trace asset ownership, licensing agreements, and commercial partnerships.
Explore the patent landscape and regulatory exclusivity around an asset.
Compare development programs by target, modality, and indication.
Connect source evidence and development news to your research questions.
See how Gosset can support your research on AAV9-shCon.